Benzinga | Aug 23, 2021 08:40AM EDT

Jaguar Health Subsidiary Napo Pharmaceuticals Submits Late-Breaking Abstract For Consideration For Presentation At 2021 IDWeek Annual Meeting

Napo Pharmaceuticals, the wholly-owned subsidiary of Jaguar Health, Inc. (NASDAQ:JAGX) today announced that an abstract associated with an exploratory clinical study on the effect of crofelemer (Mytesi(r)) on the gastrointestinal microbiome in people living with HIV/AIDS (PLWHA) has been submitted for consideration for presentation at IDWeek 2021, which takes place virtually from September 29 to October 3.

Mytesi (crofelemer) is an antidiarrheal drug indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Changes in gut microbiota of PLWHA on ART may contribute to HIV-1 related gut inflammation. This study evaluated the effects of crofelemer on the microbiota of PLWHA and HIV-negative subjects following one month of oral dosing, to test whether crofelemer's physiological mechanism of action in the gut lumen may indirectly affect the microbiota of PLWHA.

IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medical Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Diseases Pharmacists (SIDP). Additional information IDWeek 2021 can be found on the IDWeek website: https://idweek.org.